TABLE 4.

Characteristics of three SLN-positive patients by routine H&E who did not have ALND and who developed regional recurrence

Pattern of regional recurrence	Age (year)	No. of LN+/no. of LN excised	Tumor type	Tumor size (cm)	LVI	ER/PR	Operation	Local RT	Regional RT	Adjuvant systemic therapy	DFI (month)	Nomogram score (%)
Axilla	35	1/6	IDC	1.2	No	−/unknown	BCT	Breast	No	CT	11	9
Axilla	43	1/9	IDC	0.1	Yes	+/−	Mastectomy	Chest wall	SC	CT, HT	31	7
Supraclavicular	61	1/2	Invasive carcinoma with ductal and lobular features	0.35	No	−/−	Mastectomy	No	No	CT	76	26

SLN sentinel lymph node, H&E hematoxylin and eosin, LN lymph node, LVI lymphovascular invasion, ER estrogen receptor, PR progesterone receptor, RT radiotherapy, DFI disease-free interval, IDC invasive ductal carcinoma, BCT breast-conservation therapy, SC supraclavicular, CT chemotherapy, HT hormone therapy